A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
This study is currently recruiting participants.
Verified June 2013 by Hoffmann-La Roche
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01775514
First received: January 18, 2013
Last updated: June 3, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This non-interventional study will assess the occurrence rate of colon, breast and gastric cancer and of malignant melanoma in Turkey and the diagnostic methods and treatments used. Data will be collected over 12 months.
| Condition |
|---|
|
Breast Cancer, Malignant Melanoma, Gastric Cancer, Colorectal Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | OCCURRENCE RATE OF COLON CANCER, BREAST CANCER, GASTRIC CANCER AND MALIGNANT MELANOMA IN TURKEY & DIAGNOSIS AND TREATMENT CHARACTERISTICS |
Resource links provided by NLM:
Further study details as provided by Hoffmann-La Roche:
Primary Outcome Measures:
- Occurrence rate of colon cancer, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Occurrence rate of breast cancer, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Occurrence rate of gastric cancer, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Occurrence rate of malignant melanoma, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Treatment regimens used [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Clinical/demographic patient characteristics at initiation of treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Pathological analysis of tumors [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Incidence/type of surgical interventions [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Treatment regimens used in patients who have progressed to metastatic stage [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 10000 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Cohort |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Patients with colon, breast or gastric cancer or malignant melanoma
Criteria
Inclusion Criteria:
- Adult patients, >/= 18 years of age, diagnosed with colon, breast or gastric cancer of malignant melanoma
- Consent to collection of patient and family history, demographic and disease related information
Exclusion Criteria:
- N/A
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01775514
Contacts
| Contact: Reference Study ID Number: ML28579 www.roche.com/about_roche/roche_worldwide.htm | 888-662-6728 (U.S. Only) | global.rochegenentechtrials@roche.com |
Locations
| Turkey | |
| Recruiting | |
| Adana, Turkey, 01330 | |
| Recruiting | |
| Adana, Turkey, 01220 | |
| Recruiting | |
| Ankara, Turkey, 06100 | |
| Recruiting | |
| Ankara, Turkey, 06800 | |
| Recruiting | |
| Ankara, Turkey, 06500 | |
| Recruiting | |
| Ankara, Turkey, 06200 | |
| Recruiting | |
| Ba?kesir, Turkey, 10000 | |
| Recruiting | |
| Bursa, Turkey, 16059 | |
| Recruiting | |
| Bursa, Turkey, 16040 | |
| Recruiting | |
| Diyarbakir, Turkey, 41200 | |
| Recruiting | |
| Edirne, Turkey, 22770 | |
| Recruiting | |
| Erzurum, Turkey, 25050 | |
| Recruiting | |
| Gaziantep, Turkey, 27100 | |
| Recruiting | |
| Isparta, Turkey, 32260 | |
| Recruiting | |
| Istanbul, Turkey, 34890 | |
| Recruiting | |
| Istanbul, Turkey, 34300 | |
| Recruiting | |
| Istanbul, Turkey, 34000 | |
| Recruiting | |
| Izmir, Turkey, 35340 | |
| Recruiting | |
| Kayseri, Turkey, 38039 | |
| Recruiting | |
| Konya, Turkey, 42080 | |
| Recruiting | |
| Malatya, Turkey, 44280 | |
| Recruiting | |
| S?hhiye, ANKARA, Turkey, 06100 | |
| Recruiting | |
| Tokat, Turkey, 60250 | |
| Recruiting | |
| Trabzon, Turkey, 61080 | |
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
More Information
No publications provided
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT01775514 History of Changes |
| Other Study ID Numbers: | ML28579 |
| Study First Received: | January 18, 2013 |
| Last Updated: | June 3, 2013 |
| Health Authority: | Turkey: Ministry of Health |
Additional relevant MeSH terms:
|
Breast Neoplasms Colorectal Neoplasms Stomach Neoplasms Melanoma Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases |
Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Stomach Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas |
ClinicalTrials.gov processed this record on June 18, 2013